<SEC-DOCUMENT>0001178913-25-003874.txt : 20251117
<SEC-HEADER>0001178913-25-003874.hdr.sgml : 20251117
<ACCEPTANCE-DATETIME>20251117071244
ACCESSION NUMBER:		0001178913-25-003874
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251117
FILED AS OF DATE:		20251117
DATE AS OF CHANGE:		20251117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		251489309

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2 HAMAAYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		PROVINCE COUNTRY:   	L3
		ZIP:			ISRAEL
		BUSINESS PHONE:		972-8-642-9100

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2 HAMAAYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		PROVINCE COUNTRY:   	L3
		ZIP:			ISRAEL

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2534026.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div><br>
  </div>
  <div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of November 2025</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">BioLineRx Ltd.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Modi&#8217;in 7177871, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font> Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-weight: bold;"><u>CONTENTS</u></font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Attached hereto and incorporated herein is the registrant&#8217;s press release issued on November 17, 2025, titled &#8220;BioLineRx Announces
        Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types.&#8221;<br>
        <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>EXHIBIT INDEX</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z3e843969472741feb042a225308b7277" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 0.53%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
            </td>
            <td style="width: 90.44%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="exhibit_99-1.htm">99.1</a></div>
            </td>
            <td style="width: 0.53%; vertical-align: top; background-color: rgb(204, 238, 255);"><br>
            </td>
            <td style="width: 90.44%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="exhibit_99-1.htm">Press release titled:
                  &#8220;BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types.&#8221;</a></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
        signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z957d323980674012a552116d3066d124" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: bottom;" colspan="2">
              <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td nowrap="nowrap" style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Philip A. Serlin</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Chief Executive Officer</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Dated: November 17, 2025</div>
      <div style="line-height: 1.25;">&#160;<br style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25; font-weight: bold; text-align: right;"><u>Exhibit 99.1<br style="line-height: 1.25;">
        </u></div>
    </div>
    <div style="line-height: 1.25;"><img height="38" width="164" src="image0.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">For Immediate Release</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"> for Treating a Broad Range of Cancer Types</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;"> over-expressed (representing over 90% of cancers)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">Patent further broadens and strengthens GLIX1 patent protection until 2040, with a possible</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;"> patent-term extension of up to five years</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">TEL AVIV, Israel, November 17, 2025 &#8211;</font> BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing
      therapies in oncology and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent, entitled, &#8220;Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies&#8221; (Pat. Appl.
      Ser. No. 18/602,969), which covers the use of GLIX1 for treating cancer types in which cytidine deaminase (CDA) is not over-expressed beyond a specific threshold. Corresponding patent applications are pending worldwide. The patent further broadens
      and strengthens GLIX1&#8217;s patent protection for the treatment of cancer until 2040, with a possible patent-term extension of up to five years.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">It is estimated that over 90% of all cancers do not overexpress CDA beyond the specific threshold, reflecting the importance of this additional intellectual property as BioLineRx expands development
      of GLIX1 beyond glioblastoma, its initial indication, into other cancer types, once safety and dosing in glioblastoma are established.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;This Notice of Allowance from the USPTO is a critical addition to GLIX1&#8217;s intellectual property estate, as it protects our opportunity to evaluate this exciting molecule across the majority of
      cancers,&#8221; stated Philip Serlin, Chief Executive Officer of BioLineRx. &#8220;As we prepare to initiate a first-in-human study of GLIX1 in patients with glioblastoma in the first quarter of 2026, we are in parallel advancing pre-clinical studies in other
      cancer models. We believe GLIX1, with its unique mechanism of action that targets the DNA damage response in cancer cells, has the potential to offer new hope to patients suffering from a broad range of difficult-to-treat cancers, and we are eager to
      commence clinical trials early next year.&#8221;</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">GLIX1 is covered by a comprehensive portfolio of patents that are both issued and pending. In addition to the allowed U.S. patent referenced above and corresponding patents issued and pending
      worldwide, GLIX1 is covered by additional issued or pending patents, which broaden the coverage for its use in treating cancer as both monotherapy and in combination with established anti-cancer agents:</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb2a3142bf3734adfbe3aa53c1e69a927">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>GLIX1 for use in treating cancer of the central nervous system, such as glioblastoma, is covered by patents issued in the US, Europe and 13 other countries.&#160; The patents are valid until at least 2040 (with a possible patent term extension
              of up to five years).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbb1fe224b861448a8c3c1b8364b6f8dc">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>GLIX1, in combination with PARP inhibitors, for use in treating homologous recombination (HR) proficient cancers, which represent the majority of cancers, is covered by a pending international patent application. Corresponding
              national-phase patents, if granted, will be valid until at least 2044 (with a possible patent term extension of up to five years).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">About BioLineRx</div>
    <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd.&#160;(NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product, APHEXDA&#174; (motixafortide), is
      indicated in the&#160;U.S.&#160;for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by&#160;Ayrmid Ltd.&#160;(globally, except&#160;Asia) and Gloria Biosciences (in&#160;Asia).&#160;BioLineRx has retained the rights to develop
      motixafortide in metastatic pancreatic cancer (PDAC) and has a Phase 2b PDAC trial currently ongoing under a collaboration with&#160;Columbia University.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">In addition,&#160;BioLineRx&#160;has established a joint venture with Hemispherian AS to develop GLIX1, a first-in-class, oral, small molecule
        targeting DNA damage response in glioblastoma and other cancers, for which a Phase 1/2a clinical trial is expected to be initiated in the first quarter of 2026.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">Learn more about who we are, what we do, and how we do it at&#8239;www.biolinerx.com, or on&#8239;X&#8239;and&#8239;LinkedIn.</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statements</div>
    <div style="text-align: justify; line-height: 1.25;">Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These
      statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include
      statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential of GLIX1. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual
      results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ
      materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of
      market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials, and other
      therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials, whether the clinical trial results for APHEXDA will be
      predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; whether access to APHEXDA is achieved in a commercially viable manner and whether
      APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and
      commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results
      obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to
      establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues,
      capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's
      industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; and statements as to the impact of the political and security situation in Israel on BioLineRx's business, which may exacerbate the magnitude of the factors discussed above.
      These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2025. In addition, any forward-looking statements
      represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by
      law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Contacts:</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;"><u>United States</u></div>
      <div style="text-align: justify; line-height: 1.25;">Irina Koffler</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;"><u>IR@biolinerx.com</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><u>Israel</u></div>
      <div style="text-align: justify; line-height: 1.25;">Moran Meir</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>moran@lifesciadvisors.com</u></div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
  <div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !C :0# 2(  A$! Q$!_\0
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M_P#)2X__ +$F(_\ 4[+SY+Q@_P"2;P7_ &.</_ZAXX_J\_X-5/\ E'K\8_\
ML\KX@_\ JDOV>:_IDK^9O_@U4_Y1Z_&/_L\OX@_^J2_9Y_SW_I7],E?)<>?\
MEAG_ /V'/_TU3/JN!/\ DD,@_P"P"'_I=0_%/Q#_ ,'!_P#P2T\+:_KGAC6_
MC?XMM-:\.:QJ>@ZO:K\&/BS<K;:II%[/I^H6ZW%MX1EMIQ#=V\L8FMY98)0N
M^*1XV5C^H7[.W[0?PM_:H^#7@KX^?!;6[OQ'\,?B#!K-QX6UJ^T75O#UU?0Z
M#XBUCPKJ3RZ/KEI8ZK9>5K6A:E;HMW:0M-'"EQ&&AEC=O\FKX]_\ET^-/_96
M?B-_ZF&LU_I!_P#!!7_E$M^R#_V!?BM_ZOGXIU]KX@^'^2\*\/91FN78C,JN
M)Q^*P]"M'&5\-4HQA5P-?$R=.-'!X><9*I3BDY5)I0NFF[27Q'AYXA9UQ9Q%
MGF4YCALLHX;+:%>I0G@J&*IUYRI8Z&&C[65?&XB$DZ<FWR4Z;Y[--+W3]?**
M*_/;_@H__P %%_@W_P $X?@?-\3?B(\7B/QSXD:^TGX1_">RU."Q\0_$7Q)9
MP127/ENT=U-I?A701=64_BSQ.;&ZMM&AO=/M$ANM7U?1].OOR;!8+%YEB\/@
M<#0J8G%XJK&C0H4H\TZE26R2V22O*4I-1A%2G-QC%M?K>-QN%R["XC'8ZO3P
MN$PM.5;$8BM+DITJ<%=RDW]R2O*4FHQ3DTG]L>//B'X"^%GA;5?''Q,\:>%?
MA]X-T*VDO-9\5>,]?TOPSX?TNVB4N\U]J^L75G8VZ!5./,G4L<*H9B ?QE^-
MW_!Q/_P3"^#DLEEHWQ1\9_'35H)DAN=-^"?@#4M8A@W.5,R>)?'%SX!\&:A!
M&!O=]'\2:DVPCRTD?Y*_@]_;1_;W_:8_;V^(S_$']H3QY=:S!93W3>#_ (?Z
M.UUIGPW^'UG=+#'-9>#O"K7=U;V$EQ%;6R:CK%Y-?^(-9-O VKZM>F" 1<A\
M#/V+OVL_VF;"]U?X!?LZ_%WXKZ'IURUE?>(O!W@G6M2\-6M^@0OI\WB06L>A
MKJ,:2QR2:?\ VA]LCB=9G@6([Z_H+*O!;*<!@H8[C'/?J[:BZM'"U\-@L)AY
MR;M2J8_&0J*O)JR?)3PZ4U*,)5(I3?\ .^:^-V;YCCJF7\$\/O&6<U2KXG#X
MO'8O$0A92K4LNP4J<J$4]8^UJUVXN,JM.G)NG'^\KX/?\')?_!,CXHZFVE>)
M?%7Q9^!DK3)!:7GQ=^&DS:3?/(NX,FI?"_6/B;;Z?"K?NY+C73I$$;?,\@B_
M>5^SOP?^.?P;_:"\(6GC[X'_ !0\#?%;P;>LT<7B'P)XETOQ)I\=Q&=LUE>O
MIMS.^G:C;.#'=Z;J$=K?VDH:*YMHI%*C_*]^,O\ P3\_;<_9[\.7'C+XS?LL
M_&WP!X/LCC4/%VL^ ];?PMIF2JH=5\1:?;7NC:4LK,$@;4;VV6X?*0&1E8#S
M_P#9J_:E^/'[(?Q.TOXN?L^?$37/A[XQT\P0W<FF7#-I'B328KRWOIO#GBW1
M)2VF^)/#E]-:PF\TG5()[=RB3P^1=10W$6N/\&.'\SP=3%<(\0.K4CI"-?$X
M7,<#5J16M)XK!0A4P[::;DUB7%_\N[23AEE_C7Q#E6-I8/C3AQX>G.SG.AA<
M9EN/I4Y-6K+!XZ<X8E1]Y.,9852334[P:J?ZZ]%?D!_P2/\ ^"L/@'_@I9\+
M=0M=2TZR\!?M'_#33M._X6O\.H)V?2]3LY_*M(/B-X!>>66[N?!NKW[?9;S3
M;R2;5?!^L2IHNJ3W]G=:!X@\0?K_ %_/N9Y9CLGQ^)RW,<//"XS"5'2K49K5
M/1QE&2O&I3J1<:E*K!RA4IRC.$G&2;_HC+,SP.<8'#9EEN(IXO!8NFJM"O3;
MY91NTTTTI0J0DI0J4YJ,Z=2,H3C&46D445_/Y_P6>_X+3:)_P3_TM?@=\#X=
M%\9_M7>*M'BU%_[1\K4/#'P8\/WPC>Q\0^+=.20/JWB?6K9GF\*>$GDMX1:[
M?$FORKI?]E:5XFUR;)LQS_,</E>5X>6(Q>(DU&*:C"G".M2M6J/W:=&E'WJD
MY;+1*4G&+QSG.<NR#+L1FN:XF.%P6&CS5*DKN4I-VA2I05Y5:U65H4Z<$Y2D
M^B3:_9/XY_M+_L_?LS>&E\7_ +0'QB^'WPC\/S2&&SO/&_B73M&GU6Y$<DOV
M/1--GF_M77;XQ0RR+8Z/97UXR12.L!5&(_&OXK_\'+?_  3+^'.IOIOA?6?C
M5\;O*EFAEU+X6_"_['I*20 ;MMS\6/$/POGNHGDWQ07-A:7EM.R>:DQM'BN7
M_@5\?_$?X^?M:?%UO%'C[Q'\0_CO\:/B!J5EI-I+=#5?&'C#Q!?SR^1I/A[P
M]H]A#<W!B227[+HGAO0+"*SM5=;32]/A0K%7ZT?!G_@W2_X*=?%WP]%XDU/X
M<^ O@O:W6U[#3_C+X_MM$\07ELT,4JW,GA[PCIOC?6-&R\CP&R\26>BZI'-#
M*9;!(&AFF_=8>%/!O#V'H5>,^*/9XFK%25"CB</@*$GHIQHPK4Z^-Q4(2T=:
M$:&FLZ=/9?@TO%KC3B/$8BGP1PE[;"4)6EB,3A\1CJRC>\'6E0K8;!86K4BT
M_J\JN)DES<E2:3FOZG/@[_P<B?\ !,7XJ7O]G>(O&GQ2^!EU)=K:6C_&#X:7
M:Z?>%H%E%RNK?#'5/B9I>GV7F%K8W&NW>D;)D+21QVY2=OV5^#_QS^#7[0/A
M&V\>? _XH^!/BOX.NG:*/Q#X"\3:3XET^*YC.V:RO9-+NKAM.U&W8%+K3K]+
M:^M9 8[BWB<%1_G7_'K_ (-\O^"FOP(\/S^*$^$OA_XT:-9+))J/_"BO%:>-
MM<LXHT+^8G@_4M.\-^,]7#A2JQ^'_#VL3JP_>Q1JRLWYF_L^_M(_M ?L=_%:
MU^)GP+\>^*/A3\1?#]PVFZD;)G@BU&VL[^&>^\+>,O#FH1/IVO:++>V,2ZGX
M>U^PNK1I[=3+;I<P1O'-;PFX4S_"5L1P3Q.L17HI7H8C$8?&T.;WE&G6EAZ5
M'%8/VEKQJ5*5>]GRTY1=XU1\7>+>'L7A\-QWPK+"X>O)Q6*PN'Q&#K<J4'*I
M1CB*M?"8V5)2_>4J-?#M*<;RC*/+4_UUZ*_''_@D%_P5E\%_\%*OA?J>E:_I
M^G>!_P!I?X7:7I,GQ6\"6'VE-$UW3[M8K*'XD^ ?MDES.?"FJ:LLUGJ&AW%_
MJ.K>#-3DL].U:[O++5?#VLZU^QU?A&:Y7CLES#$Y9F6'GAL;A*GLZU*?2Z4X
M3A)>[.E5IRC4I5(MQJ4Y1G%M-'[WE6:X#.LOPN:99B(8K!8RG[2C6@]':3A.
M$EO"K2J1G2JTY6E3J0G"24HM!117S#^U?^UA\,OV1/AI+\0/B'<37=]J$MQI
MG@OP?II4ZWXQU^.V:X73[+<K1V5A;)LFUC6KI?L6EV\D6X7%]=:=I]Z\IRG,
ML]S+!9/D^"Q&8YGF%>&&P6"PM-U*]>M/:,(K1**3G4G)QITJ<9U:DH4X2DLL
M\SS*.&LHS'/\_P QPF4Y-E.%J8W,<RQU6-'"X3#4E>=6K4E\HPA%2J5:DH4J
M49U)QB_IQW6-&>1E1$4L[N0J(JC+,S,0%50"220 .37%67Q,^&^I>(X_!VG?
M$#P1?^+I8KF>+PM9>*]!NO$<L-DADO)H]$@OY-3>*TC!>YD6U*0("TI4#-?B
M#X<_9Z_;;_X*0VT'Q#_:/^)NL_L\_L]^)H8]2\*_!GP<NI6&L:UH,\QFTU];
MT"Z-G!/!=:=.+F+6?&[ZK=W%TMM?V?A&PLFM/)^__P!F_P#X)O\ [-?[+?C'
M3?B%\.++QK>^-],TC4-%7Q%XI\5RZG-<VFJVRVNH-<Z9I]EI&A>=<(H??;Z5
M;K$^?(2-/DK]"SK@S@SA? XW#9SQVLRXOH4:T8Y%PKE/]JY3@\?&F_983,N)
ML1C<%A)2IUKTL8LJPN8QH2C*,*U62=ORWAWQ!X_XRS++L9D/AG/)^ \36I3G
MQ+QSGKX?X@QV7.I:>-R?@G"93FN/C"M1Y:V!7$.89!7KPDI5<+0CRNI]QZKK
M>C:%!'=:YJ^F:-;2RB"*XU6_M=.@DG*/((8YKN6&-Y3''(XC5BY1'8#:K$7K
M>X@NX(;JUFBN;:YBCGM[BWD2:">"9!)%-#-&6CEBEC97CD1F1T8,I((->6?&
M_P""W@+]H/X8^*/A/\2=(BU;PQXHLQ%)F.(WNDZE;N+C2M?T>>6.3[%K6BWR
M0WVG7B+F.:((XD@DFBD_+7]ASXR^.?V7/BY<_P#!.?\ :4U.&>]T*TAN?V;?
MB+(QMM,\9^"II;N/1_#$:75W</8K);V<T?A'3OM%TNFW6FZUX'-TTNDZ$NH>
M%DG"$>(N&\\S/*<=*OG_  ZO[1S#AR6'4:N)X;C%1Q6<Y9B(U92Q4\KKN']J
M8%T*=2A@ZD,=2JUJ<,1"A]+Q%QW_ *J<6<-9/GF71PW#?%DO[)ROBN.*<J&&
MXOG4O@.',VP;PT5@HYWAU4_L7,UC*M+%9A0J976H8:O5P4\7^T5%%%?$GZ$%
M9&J>(-!T1[6/6M;TC2)+UG6R35-2L[![MHS&LBVJW<T37#(TT0<1!RIEC#8+
MKGF_B=\2_!?P>\!>*/B7\0M;MO#_ (/\(:7-JNLZG=,HVQH5BM[.TB+*UYJ>
MI7DMOIVE:?#NN=1U*ZM;*V1YYXT/Y#_LF_#'QA^W+\>+K]O']H71)8/AIX7U
M%[']E'X9:NB2V-A9:7>2>3XUO=/EM%@O$L+R%-1TW49Y+B;4O&S7NKVRV&G>
M%_#"S?:\.<)0S3)\\XFSC'RR;AS)*3H1QBPRQ.(S?/\ $4W++N'\JP\ZV'C7
MQ=;_ 'G'575]EEF6TZF,KJ3EAZ-?\^XJXZ>2\0<,<'Y)EG^L'%7$N)^L2R^.
M*^J8?(N%\'/_ (6.*\\Q4,/BY83+\-[N!RRE[!U<ZSS$X3+,-*G!XS%X+]LZ
M***^*/T$**** /\ &GK]M?\ @B-_P2\C_P""B/Q^U+7?B=!?0?LS_!%]*U?X
MH?9)Y["[\>:[J33R>&?A=IFI6MQ;7NGQ:RMG=ZGXJU?37-[IGARPDL+2?2]7
M\0Z+JMI^)5?Z2G_!NU\)[+X9_P#!+7X,ZVNEV^G:W\8/%/Q/^*/B*2-+?[1J
M$UQXXU?P5X>OKN>W9_/>;P7X*\,M )7,UO;&*VE2&6*2%/[0\5.),5PWPK5J
MX"JZ..S'%4\LP]>+M5P\:U*O6KXBEJI*I&A0G3IU8ZT:M6G4BU.,3^)_"/AK
M!\2\60AF-+VV!RO!U<TJT)T^>AB:M*MAZ&'PU>Z<>253$>WE3E=5H8>=-Q<)
M3M^R_@/P#X)^%WA#P_X ^''A/P_X'\$>%-,M=&\-^%/"VE6>BZ%HNF642PVU
MGI^FV$4-M;Q1QHH.R/=(V9)&>1F8];117\8RE*<I3G*4IRDY2E)N4I2D[RE*
M3NW)MMMMW;U9_:\8QA&,8Q48Q2C&,4HQC%*RC%*R225DDK):(XOXB?#GP%\6
M_!?B'X<_$[PAX?\ 'G@7Q9IMQI'B/PKXHTRUU?1=7T^ZC:.:"[LKN.2,G:VZ
M&9 EQ;3!)[:6*>-)%_S;_P#@M+_P3)D_X)T?M%VB^!!J.H?LZ_&:+5O$WPAU
M"^DGO;SPS<6%Q /$_P -=9U%[>);J]\+SW]E<:+=R//<ZCX6U+29+RZN]7M-
M8F7_ $Q*_ /_ (.3_@G9_%+_ ()H>*/'9>>/6/V??BA\./B?IBVZV^;ZUUK5
MG^$^MZ;=--&SBP33_B,=?E6V>&=KOP_8Y=X5E@F_1_"WB7%Y%Q3E^$5>2R[.
M,52R_&8:4G[&53$R5'"XA1^&%6C7E2_>V3]BZD)/DD[?FOBKPSA<_P"$\RQ+
MP\99ED^%K9C@<1&*]M&.&C[;%8=-+FG3KX>%5>QNTZJI3BG.$3\0?^#8K]N3
M6?AS^T'XC_8D\8ZP)/AU\==/UCQ?\-+>]ENY#X?^+_A'2FU34M.TGYS9V5AX
MX\#Z=K,^JK<*/.UOPCX;AL&CN=1O$OO[NJ_R5/V%?BI>?!+]L[]EGXJVET;-
M?!?QZ^%^J:G+\H$GAZ3Q=I5CXGLW+$*L6H>'+O5+"5LJ5BN78,I (_UJZ]OQ
MLR:CEW$^'S##TXTXYS@O;UXQ5E+&X:HZ->I9)).I2>&E-K6=7VDY>])M^'X'
M9U7S+A2O@,34E5GDN/EA</*6KC@:]*%?#T^;>7LJKQ,()Z0HJE3C[L4E_F3_
M /!>[_E+7^U[_P!A;X1_^J ^%-?TB?\ !J3_ ,F<?M%_]G,3?^JM^']?S=_\
M%[O^4M?[7O\ V%OA'_ZH#X4U_2)_P:D_\F<?M%_]G,3?^JM^']?>\;?\F:R+
M_L6<)_\ J)A3\]X%_P"3U<0_]C/B[_U-Q)_4D[K&C22,J(BL[NY"HB*"S,S,
M0%50"68D  $DXK_+O_X*_P#[<6O?MT_MK_$SQO'JSW/PI^'6L:M\+?@EI-KJ
M4E_HD'@3PMJUW8_\)58*JQ6OVWXBZE#<>,-0ND@-Q]EU#2M&EN[RTT+3Y%_T
M8_V[_B-<?"+]BC]K3XF64CQ:GX+_ &<_C)KNBO&[1.-?M? &O?V !*H+0AM:
M>Q1IE5FA5C*J.4"G_)6KP/ C):-;%9QGU:"E5P<:& P3>O)/$QJ5,7-*^D_9
M0H4XRM\%6JD]6?0^/N=UJ&"R7(*-1QIXZ>(Q^.BKKGIX25*G@X2?+:4)5IUZ
MCBI:3H4Y2C\+/ZO?^#>S_@D-X%_:%L'_ &V_VG?"ECXO^%^B^(M1T'X)?#+7
M[>VU#PSX\U_P_+)8^(O''B[2IEF@UCPUX<UE9=#T/0;X&RU7Q'I>LSZS97&G
M:79PZC_<K;V]O:00VMI!#;6MM%'!;VUO$D,$$$2A(H888U6.**-%5(XT5410
M%4  "OFO]B[X.0_L^?LC_LU_!2,69N/AI\$_AQX6U:XL;-+"VU'Q'8>%M-'B
M?6%M(YKA89=:\1/JFKW(-S<R/<WLLDMS<2N\S_35?E'&7$^,XJSW&9AB*M1X
M:-:K2R[#.3=/"8*,VJ,(1ORJI."C4Q$TDZM:4I.RY8Q_7>#.&,%PID.!RW#4
M*<,1["C5S*O&*]IB\PE2C]8K5)WE*454<H4(.4HT:*A3@[*[*^;?VJOV2_@5
M^V=\(M?^"_Q]\%6'BSPMK-O<'3=0\N&#Q-X-UM[>6"R\5^"]<,,MSH/B/2WD
M\ZUNX0]M<J'L-5L]1TJYO+"X^DJ*^9H5ZV&K4L1AZM2A7HSC5HUJ,Y4ZM*I!
M\T9TYQ:E&46DU)--,^FK4:.)HU</B*5.O0K0E2K4:L(U*56G-.,Z=2$TXSA*
M+:E&2::=FC_)M_;V_8Y\;_L'_M1_$K]G'QK+-JB>%KVVU3P7XL-A=V-GXX^'
MVOP_VAX4\4V'VFW@BF:>S9]*UQ;!KJPTWQ9I/B'0HKVYDTF:2OZ_?^#8S]N6
M_P#B]\!_&W[''Q!\1#4?&?[/"6WB3X6C4KVYN=9U/X+>(;][>[TJ)[R[N9[J
MQ^&WBRYM]*M_*6VL]'\/^+?".@V=NEKIT('SY_P=C?!S3WT;]D;]H&U"1:K;
MZIX_^#FN-L!DOM/O+33O&OA4;]X94TJYL?&1VB)U=M9RSQF-5E_(K_@W2^*&
MI?#S_@J=\'= M%!T[XP>#/BS\,M?.[#)IZ> ]7^(VGNB^5(9"?$OP]T&)U#P
M!8I))FE(B,4O]1YG6_U^\(YYGBH1EF67X2KCIU/=CRXS)95(XRM'W8Q7UO!4
MZ]1TXI13Q"IQ;<(L_E?+*7_$/O&*.4X.<H95FF+H8*%&\Y1EA,ZA3E@Z+2E*
M3>#Q]2E2A4J7ER47.34:DF?Z1M?Y;_\ P6P_Y2J?MH_]E.T__P!0;PC7^I!7
M^6__ ,%L/^4JG[:/_93M/_\ 4&\(U^9>#?\ R4N/_P"Q)B/_ %.R\_5O&#_D
MF\%_V.</_P"H>./ZO/\ @U4_Y1Z_&/\ [/+^(/\ ZI+]GFOZ9*_F:_X-5/\
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M'I%I#8:5HVCV-KIFE:98VR".WL]/T^RB@M+.U@C 2&WMX8XHT 5$ &*^1?\
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M_LIVG_\ J#>$:_U(*_RW_P#@MA_RE4_;1_[*=I__ *@WA&OS'P;_ .2EQ_\
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MZE*=*='ZQ@JU&--PJTZCDJTZ<XN#E'^OK_B$?_ZR!_\ FJ7_ .4E1_Q"/_\
M60/_ ,U2_P#RDJ_<#_@DE_P5 ^'7_!1'X": ^HZ_HNE?M->!-#LM.^-?PX,]
MM9:G<:C8I#8R?$?PSI82W^V>"_%DQBU -IL4UOX7U6]E\-7[J]O876H_K97Y
MCF7B1XFY1CL3EV89Q/#8S"594JU*IE.2)J4=I1?]FVG3J1M.E4BW"I3E&<).
M,DW^HY;X9>%V;X'#9EEV2T\5@\92C6H5J><9XXRC);27]IWA4@[PJTY)3I5(
MRIU(QG&27\:?_$(__P!9 _\ S5+_ /*2H_XA'_\ K('_ .:I?_E)5_997/\
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MUN(,WIU)X3+:N!K5EE."^LXB=6&-KTJ=#\?XOX6S[Q!XLP'#^=8+ZEX5Y#'
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MV;^U>3SR?VB?B^?7_J<,<<=?QXKQ8> ^:SM_POY>FU_T"XGR_O>?_ /1J_2
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MR3_PV8__ .6^O]/2/^*D7!G_ $;3BC_P\95_\J]?Z>G][=%?P2?\-7?M1_\
M1R?Q]_\ #Q?$3_YHZ/\ AJ[]J/\ Z.3^/O\ X>+XB?\ S1T?\26\2?\ 1;Y)
M_P"&S'__ "WU_IZ'_%2+@S_HVG%'_AXRK_Y5Z_T]/[VZ*_@D_P"&KOVH_P#H
MY/X^_P#AXOB)_P#-'1_PU=^U'_T<G\??_#Q?$3_YHZ/^)+>)/^BWR3_PV8__
M .6^O]/0_P"*D7!G_1M.*/\ P\95_P#*O7^GI_>W17\$G_#5W[4?_1R?Q]_\
M/%\1/_FCH_X:N_:C_P"CD_C[_P"'B^(G_P T='_$EO$G_1;Y)_X;,?\ _+?7
M^GH?\5(N#/\ HVG%'_AXRK_Y5Z_T]/[VZ*_@D_X:N_:C_P"CD_C[_P"'B^(G
M_P T=?7W[$W_  4A^+WP*^-.G:K\8OB5\1_B=\*/%*6OA[QOI?C'Q=XB\93>
M'[-KAFL_%_AN+7;S59[/4=!EGEGO[/2_)/B#2GN+"YCGO(-&GT_R<]^AYQCE
M>3YCF.7\1Y3G6,P.%JXJCE5#!XS#XC'NC'GGA\-5JRG3^L3@I^PA-*-6JH4G
M.'/SQ]_A7]H9X<Y[Q%E&39OPEG_#&7YGC:."KY_C<PR[%8'*WB)*G2Q6.IT8
MTZL<%"K*'UJO!R>&H.>(<)QIRB?V.T5EZ)K>D>)=&TKQ#H&HVFKZ'KFGVFJZ
M1JMA,ES9:CIM_ ES9WMK/&2DL%Q;R1RQ.I(96!HK^0IPG3G*G4C*$X2E"<)Q
M<9PG%N,HRBTG&46FI1:33335S_0.$XU(1J4Y1G"<8SA.#4H3A)*491E%M2C)
M-.,DVFFFG8U****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^/?VL/V'/V2OVO?#%Y:_M&? ?P)\2[NQL1_9WB6]L[O0?'>E16+-=P6
MFD?$3PG>Z#X[TG3S.-USING>([6PO4+0WMM<0LT9_"C4_P#@CA_P3?M-0NH;
M?]G/RXXII$1?^%O?'=]JK(P R_Q/9CCU))]3117T>3YYG6!IRP^"SC-,'03<
ME0PN88O#T5)M7DJ=*K""D^KY;L\/,\BR3,*BKX_)LJQU?X?;8S+L)B:O*EI'
MVE:C.=ET5[(JK_P1_P#^"=2?=_9XQSG_ )*U\<S_ #^)AJ>/_@D/_P $\%(
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MT_YG6K/_  [W_9 _Z)%_Y?WQ/_\ FUHHKICX@\?6_P"2WXOZ?\U+G/\ *O\
MJ-.%^#?A"]7X5>&[?GP-PP__ 'EA_P .]_V0?^B1?^7]\3__ )M:/^'>_P"R
M#_T2+_R_OB?_ /-K115?\1!X^_Z+?B__ ,27.?\ YM%_Q!KP@_Z-3X;?^(-P
MQ_\ .L/^'>_[(/\ T2+_ ,O[XG__ #:T?\.]_P!D'_HD7_E_?$__ .;6BBC_
M (B#Q]_T6_%__B2YS_\ -H?\0:\(/^C4^&W_ (@W#'_SK#_AWO\ L@_]$B_\
MO[XG_P#S:T?\.]_V0?\ HD7_ )?WQ/\ _FUHHH_XB#Q]_P!%OQ?_ .)+G/\
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A"X7#4(*E0P^&P]&,*5"A1I1C3I4J4(TZ=.,80BHI(__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
